Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: $Mogul who wrote (61615)	1/12/2000 6:02:00 PM
From: Wes Stevens	Respond to of 108040

Thanks $Mogel

To: $Mogul who wrote (61615)	1/12/2000 6:15:00 PM
From: swisstrader	Read Replies (1) \| Respond to of 108040

ISIS - a bit more background: ANTISENSE DRUG CAUSES REDUCTION OF C-RAF-1 RNA LEVELS IN CANCER PATIENTS; NEW DATA ON ANTISENSE MECHANISM OF ACTION IN HUMANS WEDNESDAY, JANUARY 12, 2000 2:59 PM - PRNewswire CARLSBAD, Calif., Jan 12, 2000 /PRNewswire via COMTEX/ -- Dr. Peter O'Dwyer and colleagues currently at the University of Pennsylvania and scientists from Isis Pharmaceuticals (Nasdaq:ISIP) published results from a human clinical trial in patients with advanced cancer that show that an antisense drug, ISIS 5132, reduced the levels of target RNA, c-raf-1 after intravenous administration. The paper is entitled: "c-raf-1 Depletion and Tumor Responses in Patients Treated with the c-raf-1 Antisense Oligodeoxynucleotide ISIS 5132 (CGP 69846A)" by Peter J. O'Dwyer, James P. Stevenson, Maryann Gallager, Amy Cassella, Irina Vasilevskaya, Brett P. Monia, Jon Holmlund, F. Andrew Dorr, and Kang-Shen Yao of Thomas Jefferson University, and Isis Pharmaceuticals and was published in the December 1999 issue of Clinical Cancer Research. In this study, patients with advanced cancer were treated with ISIS 5132 administered intravenously three times weekly. Peripherial blood mononuclear cells were collected from patients at several times during treatment. The effects of ISIS 5132 on c-raf-1 mRNA levels in these cells were measured. After a single dose of ISIS 5132, 13 of 14 of the patients treated showed dramatic reduction in c-raf-1 mRNA levels. (p=0.002). Reductions in c-raf-1 mRNA were observed at all dose levels, were particularly striking in patients in whom clinical benefits were observed. "This study shows that ISIS 5132 produces effects consistent with an antisense mechanism in patients after intravenous administration." said Andrew Dorr, M.D., Vice President of Isis. "This adds to the increasingly compelling body of data showing that antisense drugs work as anticipated in human beings by selectively reducing the RNA they were designed to inhibit." This press release contains forward-looking statements pertaining to the potential of ISIS 5132, an antisense drug currently in clinical trials as a treatment for cancer. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Actual results could differ materially from those projected in this release. As a result, the reader is cautioned not to rely on these forward-looking statements. These and other risks concerning the therapeutic potential of antisense drugs are described in additional detail in Isis' Annual Report on Form 10-K/A for the year ended December 31, 1998, which is on file with the U.S. Securities and Exchange Commission, copies of which are available from the company. Isis Pharmaceuticals, based in northern San Diego County, is engaged in the discovery and development of novel human therapeutic drugs. The company's first product, VitraveneTM (fomivirsen), to treat CMV-induced retinitis in AIDS patients, is being sold in the United States, Europe and Brazil. In addition, Isis has four compounds in human clinical trials: a Phase II of ISIS 2302 for the prevention of renal transplant rejection is near completion, Phase II studies with an enema formulation for ulcerative colitis and a topical formulation for psoriasis, are just beginning and an aerosol administration for asthma is being explored. In addition, Isis has three anticancer compounds: ISIS 3521, ISIS 5132 and ISIS 2503, in Phase II studies. The company also has several additional compounds in preclinical development. Isis' medicinal chemistry and biology research programs support efforts in both antisense and small molecule drug discovery.